HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants with HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer

MSD K.K.0 个研究点目标入组 3 人开始时间: 待定最近更新: 2025年5月12日

试验速览

暂无简介。

•The main inclusion criteria include but are not limited to the following:
•Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer.
•Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART).
•Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation.
•Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention.
•Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting.
•Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment.
•Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting.
•Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

•The main exclusion criteria include but are not limited to the following:
•Uncontrolled or significant cardiovascular disease.
•History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/interstitial lung disease.
•Has clinically severe respiratory compromise.
•Has any history of or evidence of any current leptomeningeal disease.
•Has clinically significant corneal disease.
•Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
•HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
•Known additional malignancy that is progressing or has required active treatment within the past 3 years.
•Evidence of spinal cord compression or brain metastases.
•Has an active infection requiring systemic therapy.
•Concurrent active HBV and HCV infection.
•Has had major surgical procedure (excluding placement of vascular access) less than 28 days.
•Arm 3 ONLY:
•Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting.

Safety and tolerability

未报告次要终点

发起方